<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204784">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000180</url>
  </required_header>
  <id_info>
    <org_study_id>IA0008</org_study_id>
    <secondary_id>3U01AG010483-08S2</secondary_id>
    <nct_id>NCT00000180</nct_id>
  </id_info>
  <brief_title>AIT-082 Phase 1B Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Aging (NIA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIT-082 is a novel small molecule that crosses the blood-brain barrier to enhance nerve
      function by increasing levels of neurotrophic growth factors and encouraging nerve sprouting
      in the brain. Preclinical studies in animals have shown that AIT-082 improves memory in aged
      animals and in animals with neurological deficits.

      This study was a double-blind placebo-controlled safety study that was designed to study
      whether AIT-082 may delay age-related mental decline. Eight healthy older volunteers at two
      clinical sites were given single, weekly, rising doses of AIT-082 or placebo for 5 weeks;
      were tested for side effects and absorption; and underwent a battery of neuropsychological
      memory tests, including word and number recall tests.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <condition>Memory Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIT-082</intervention_name>
  </intervention>
  <eligibility>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Grundman, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093-0949</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Alzheimer's Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ; Alzheimer's Disease Cooperative Study. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. 2003 Jun 20;73(5):539-53.</citation>
    <PMID>12770610</PMID>
  </results_reference>
  <verification_date>February 2005</verification_date>
  <lastchanged_date>December 10, 2009</lastchanged_date>
  <firstreceived_date>October 29, 1999</firstreceived_date>
  <keyword>Memory</keyword>
  <keyword>Mild cognitive impairment</keyword>
  <keyword>Nerve growth factors</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
